Syndax CMO sells 65,515 shares after option exercise
Syndax Pharmaceuticals Head of R&D and CMO Nicholas A.J.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Syndax Pharmaceuticals Head of R&D and CMO Nicholas A.J. Botwood reported an exercise-and-sell pattern in company stock. On June 11–12, he exercised stock options to acquire a total of 53,750 shares of common stock at $13.82 per share and sold 65,515 shares in open-market transactions around $18 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 60,885 common shares and has 16,537 vested and 289,413 unvested options to purchase additional shares.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
Botwood Nicholas A.J.
Role
Head of R&D, CMO
Sold
65,515 shs ($1.18M)
Approx. gross sale proceeds
$1.18M
Approx. exercise cost
$743K
Share of Position Sold
51.8%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock options (Right to buy) | 31,235 | $0.00 | $0.00 |
| Exercise | Common Stock | 31,235 | $13.82 | $432K |
| Sale | Common Stock | 31,235 | $18.14 | $567K |
| Exercise | Stock options (Right to buy) | 22,515 | $0.00 | $0.00 |
| Exercise | Common Stock | 22,515 | $13.82 | $311K |
| Sale | Common Stock | 34,280 | $18.00 | $617K |
Holdings After Transaction:
Stock options (Right to buy) — 0 contracts (Direct);
Common Stock — 60,885 shares (Direct)
Holdings Before and After:
Common Stock, 72,650 to 60,885 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (4)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested.
- F2. These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date.
- F3. These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date.
- F4. The shares sold in this transaction were fully vested.
Key Figures
Shares sold: 65,515 shares
Sale prices: $18.00 and $18.14/share
Options exercised: 53,750 shares
+4 more
7 metrics
Shares sold
65,515 shares
Open-market sales on June 11–12
Sale prices
$18.00 and $18.14/share
Weighted-average sale prices on June 11–12
Options exercised
53,750 shares
Options exercised at $13.82/share
Common shares held
60,885 shares
Direct holdings after transactions
Vested options remaining
16,537 options
Vested, immediately exercisable options after transactions
Unvested options remaining
289,413 options
Unvested options to purchase common stock
Net share change
-65,515 shares
Net buy/sell direction reported as net-sell
Key Terms
Rule 10b5-1 plan, weighted-average sale price, stock options (Right to buy), vested and immediately exercisable, +1 more
5 terms
Rule 10b5-1 plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted-average sale price financial
"The price reported above reflects the weighted-average sale price of all transactions executed on that date."
stock options (Right to buy) financial
"Stock options (Right to buy)"
vested and immediately exercisable financial
"a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable"
unvested financial
"a total of 289,413 options to purchase shares of common stock that have not yet vested."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Syndax (SNDX) report for Nicholas Botwood?
Syndax reported that Head of R&D and CMO Nicholas Botwood exercised options for 53,750 shares and sold 65,515 common shares. The sales, executed around $18 per share, were carried out under a pre-arranged Rule 10b5-1 trading plan.
What options did Nicholas Botwood exercise in this Syndax (SNDX) Form 4?
Botwood exercised stock options to buy 22,515 shares and 31,235 shares of Syndax common stock, both with a $13.82 exercise price. These exercises converted previously granted options into common shares that were then partly sold in the market.
What remaining options does Nicholas Botwood have in Syndax (SNDX)?
After the reported exercises, Botwood retains 16,537 vested options and 289,413 unvested options to purchase Syndax common stock. The vested options are immediately exercisable, while the unvested options are scheduled to vest over time under their grant terms.
Were the Syndax (SNDX) insider sales by Nicholas Botwood pre-planned?
Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted by Nicholas Botwood. Such plans pre-schedule trades, making the timing more mechanical and less reflective of short-term views on Syndax’s share price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
